Meric Coskun

Dr. Meric Coskun

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2024 in Journal of Endocrinological Investigation
Verified
Journal Article
Open access
PDF file
MCMeric Coskun
Meric Coskun
HSH. N. Sendur
H. N. Sendur
ABA. Babayeva
A. Babayeva
MCM. N. Cerit
M. N. Cerit
ECE. T. Cerit
E. T. Cerit
FTF. B. Toruner
F. B. Toruner
Purpose: The liver is known to be protected from steatosis under the influence of high GH/IGF-1. Cytokeratin 18 (CK18) and insulin-like growth factor binding protein 7 (IGFBP7) increase in liver steatosis and fibrosis. The aim of this study was to use quantitative ultrasound techniques and biochemical markers to assess liver steatosis and liver fibrosis in newly diagnosed acromegaly. Methods: This single-center, cross-sectional study included 23 patients with newly diagnosed acromegaly and 46 age, sex, body mass index (BMI) and waist circumference (WC)-matched controls. Liver steatosis was assessed using tissue attenuation imaging (TAI), and stiffness, indicative of fibrosis, was assessed by shear wave elastography (SWE). Serum IGFBP7 and CK18 were studied by ELISA. Results: The acromegaly group had significantly lower liver steatosis (p = 0.006) and higher liver stiffness (p = 0.004), serum IGFBP7 (p = 0.048) and CK18 (p = 0.005) levels than the control group. The presence of fibrosis (p = 0.012) was significantly higher in the acromegaly group than in the control group. Moreover, CK18 was positively correlated with liver stiffness, WC, HOMA-IR, HbA1c, and triglyceride. In the acromegaly group, liver steatosis was negatively correlated with GH level. Stepwise multiple linear regression analysis revealed that BMI (p = 0.008) and CK18 (p = 0.015) were independent risk factors for increased liver stiffness. Conclusion: This study showed that there was an increased presence of liver fibrosis independent of liver steatosis in newly diagnosed acromegaly. Serum CK18 appears to be a potential marker of increased liver fibrosis in acromegaly.

30 October 2023 in Pituitary
Verified
Journal Article
Closed access
PDF file
MCMeric Coskun
Meric Coskun
HSHalit Nahit Sendur
Halit Nahit Sendur
MCMahi Nur Cerit
Mahi Nur Cerit
ABAfruz Babayeva
Afruz Babayeva
ECEthem Turgay Cerit
Ethem Turgay Cerit
FTFusun Balos Toruner
Fusun Balos Toruner

17 December 2025 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
TBTuğba Barlas
Tuğba Barlas
AAAlev Eroğlu Altinova
Alev Eroğlu Altinova
MCMeric Coskun
Meric Coskun
ECEthem Turgay Ceri̇t
Ethem Turgay Ceri̇t
The global prevalence of obesity and metabolic syndrome (MetS) is rising worldwide, and increasing evidence suggests that chemical exposures—particularly endocrine disruptors (EDs)—represent a significant contributing factor. EDs can act as obesogens, increasing the risk of weight gain and related metabolic conditions, including type 2 diabetes, dyslipidemia, hypertension, and cardiovascular disease. They may also alter the basal metabolic rate, gut microbiota composition, and hormonal regulation of appetite and satiety. EDs are reported to exert their effects mainly through the peroxisome proliferator-activated receptor gamma pathway, which is primarily expressed in adipose tissue and is a key regulator of adipogenesis. Common consumer products such as plastic bottles, metal food cans, detergents, toys, cosmetics, and pesticides frequently contain EDs. Humans can be exposed to these chemicals via multiple routes, including transplacental transfer, breast milk, inhalation, ingestion, and dermal absorption. Bisphenols, tributyltin, phthalates, per- and polyfluoroalkyl substances, polycyclic aromatic hydrocarbons, and heavy metals are among the known EDs that have been associated with obesity and MetS. The need for further investigation and stricter regulations to mitigate the public health consequences of environmental exposure to EDs is consistently emphasized in recent literature. Understanding the mechanisms by which EDs affect various hormones and systems is essential for developing effective prevention and intervention strategies. In this review, we discuss the relationship between obesity, MetS, and EDs, along with exposure pathways and preventive strategies.

31 May 2024 in Endocrine
Verified
Journal Article
Closed access
PDF file
ABAfruz Babayeva
Afruz Babayeva
COCeren Ozkul
Ceren Ozkul
MCMeric Coskun
Meric Coskun
AUArzu Uzun
Arzu Uzun
MYMehmet Muhittin Yalcin
Mehmet Muhittin Yalcin
AAAlev Eroglu Altinova
Alev Eroglu Altinova

21 January 2025 in Journal of Eating Disorders
Verified
Journal Article
Open access
PDF file
ABAfruz Babayeva
Afruz Babayeva
SAShovket Alishova
Shovket Alishova
GMGunay Mammadova
Gunay Mammadova
MCMeric Coskun
Meric Coskun
ECEthem Turgay Cerit
Ethem Turgay Cerit
MYMehmet Muhittin Yalcin
Mehmet Muhittin Yalcin
Adults with type 1 diabetes (T1D) are reported to be at higher risk for clinical eating disorders (ED) and other disordered eating behaviors (DEB) than their peers without diabetes. On the other hand, there is insufficient data on DEB in adults with type 2 diabetes (T2D). Our study aimed to investigate the prevalence of DEB in patients with T1D and T2D on intensive insulin therapy followed in our outpatient clinic. Diabetes Eating Problem Survey-Revised (DEPS-R), electronically delivered to the patients with T1D and T2D who were on an intensive insulin regimen followed up in the diabetes outpatient clinic in our center for the evaluation of DEB. A total of 120 participants, 80 patients with T1D and 40 patients with T2D, were included in the study. DEB was defined as a DEPS-R score ≥ 20 according to the answers given to the questionnaire. Risk of DEB was observed in 35% of all individuals with diabetes and was higher in T2D (55% (n = 22)) than in T1D (25% (n = 20)) (p < 0.001). In patients with T1D, BMI was similar between the risk and normal groups in terms of DEB (p = 0.15), whereas in patients with T2D, BMI was significantly higher in the risk group in terms of DEB compared to the non-risk group (p < 0.001). There was a positive correlation between the risk of DEB and HbA1c and a negative correlation with the duration of diabetes in the T1D group (p < 0.05). Weight loss was an important goal for more than 50% of individuals with diabetes in both groups, more than 60% said they skipped a main meal or snack. 13.8% of those with T1D and 27.5% of those with T2D preferred being thin to having their diabetes better controlled. In our study, 35% of patients with diabetes were found to have a risk of DEB, with the risk being higher in the T2D group. Our results emphasize the importance of increasing awareness among physicians and patients about DEB, which is prevalent among patients with diabetes. Early detection of individuals at risk for DEB should be considered a crucial aspect of treatment. Studies have reported that adults with diabetes are at a higher risk for eating disorders (ED) compared to their peers without diabetes. However, this issue has not been thoroughly explored in adults with type 2 diabetes (T2D). Therefore, our aim was to investigate the prevalence of disordered eating behaviors (DEB) in patients with type 1 diabetes (T1D) who were receiving intensive insulin therapy, as well as in patients with T2D at our outpatient clinic. The Diabetes Eating Problem Survey-Revised (DEPS-R) was electronically delivered to the participants for the evaluation of DEB. The survey results, revealed that 35% of all individuals with diabetes exhibited a risk of DEB, with a higher prevalence in those with T2D compared to those with T1D. In patients with T1D, the body mass index (BMI) was similar between risk and non-risk groups in terms of DEB. However, in patients with T2D, the BMI was significantly higher in the at-risk group than in the non-at-risk group. Additionally, over 50% of individuals with diabetes in both groups identified weight loss as an important goal, and more than 60% admitted to skipping meals or snacks. Interestingly, 13.8% of patients with T1D and 27.5% patients with T2D expressed a preference for being thin over having better of their diabetes. Our study underscores that 35% of individuals with diabetes are at risk for DEB, with a higher risk in the T2D group. These findings emphasize the necessity of increasing awareness among physicians and patients regarding the prevalence of disordered eating behavior among patients with diabetes. Early identification of individuals at risk for DEB should be considered an essential component of treatment.

17 December 2025 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
MCMeric Coskun
Meric Coskun
ECEthem Turgay Ceri̇t
Ethem Turgay Ceri̇t
TBTuğba Barlas
Tuğba Barlas
AAAlev Eroğlu Altinova
Alev Eroğlu Altinova
Endocrine-disrupting chemicals (EDCs) are compounds that interfere with hormone synthesis, secretion, metabolism, or excretion. Evidence indicates that increased exposure to EDCs is associated with insulin resistance and, most notably, type 2 diabetes worldwide. This suggests a diabetogenic effect that is independent of obesity, underscoring the complex mechanisms and broad impact of EDCs on metabolic health. Key pathways include hormone mimicry and antagonism, altered hormone metabolism, inflammatory responses, and mitochondrial dysfunction. This review summarises the mechanisms through which EDCs contribute to these conditions and evaluates the epidemiological and experimental evidence supporting these associations.